



Conference Call

SEB Conference Call

Tom Rönnlund, CEO
Henrik Lundkvist, CFO

Lund, 2nd November 2020



Safe Harbor Statement

This presentation contains certain forward-looking information that reflects Probi's present view of future events, as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information. Given the risks associated with forward-looking statements, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. Probi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

Probi does not make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. Probi does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.





Agenda

- 1 Introduction
- 2 Q3 summary
- 3 Q&A

Probi – "First in probiotics"




Founded 1991



420 patents



40 markets




626 MSEK Net Sales
183 MSEK EBITDA



170 employees



4.500 MSEK Market Cap



Probiotics are live micro-organisms (bacteria) which, when administered in sufficient amounts, confer a health benefit on the host. (WHO)




Trends driving future probiotics market

Reconciliation of group liquidity SEK m



Probiotics – Supplements Expected global growth 2019-2024 (USD bn consumer value)¹



¹ Source: Global Probiotics Market Insights – Euromonitor December 2019.

Strategic focus

Doubled sales

Growth

- Stronger presence in growth markets
- Solidify position in premium probiotic segments
- Strategic partnerships
- Acquisitions

Lead the way in probiotic innovation and science

Accelerate development of new products

- Expand range of clinically documented offerings
- Increase international collaborations
- Evaluate growth potential in probiotic related market segments

Manufacturing excellence

More efficient manufacturing

- High quality production adapted to market needs
- New manufacturing capabilities in growth regions
- Gradually improved gross margins





Agenda

1 Introduction

2 Q3 summary

3 Q&A

Strong growth in Q3

- Net sales growth by 38% driven by strong development in region Americas
- EBITDA margin 32% in Q3 and 28% YTD
- Weaker development in EMEA and APAC as result of earlier stock build-up
- New management team complete with recruitment of VP R&D
- New research study showing link between probiotics and reduced side-effects related to acute stress
- Generally limited impact of COVID-19 on Probi operations
- Acquisition of shares and strategic partnership with Vital Nutrients Holdings




Strong sales growth with good profitability in Q3

Net sales

SEK m, sales growth in % (constant currency growth)


Target
> 7 %



EBITDA %

EBITDA margin as % of Group net sales

Target
≥ 29 %



Highlights in the quarter

- Net sales (organic) growth by 38%
- Positive one-off effect in the quarter of SEK ~15 m from customer update program in region Americas
- Higher sales and product mix delivered good margin
- Higher OPEX in Q3 reflecting increased activity levels





Agenda

1 Introduction

2 Q3 summary

3 Q&A



Financial calendar

Year-end report 2020: 9th February 2021

